TITLE:
The Polymorphism and Transformation of (3aRS, 4RS, 7RS, 7aSR)-2-(Tricyclo[3.3.1.13,7]decan-1-yl)-4,5,6,7-tetrahydro-4,7-eposyisoindoline-1,3-dione (SU2162)—A Novel Anticancer Compound
AUTHORS:
Yuqing Huang, Zaiyou Tan, Lin Luo, Hui Yang, Chunmei Tong, Wenfei Chen, Tingyu Huang, Ruiling Liu
KEYWORDS:
SU2162; Polymorphism; Crystal Form; Melting Method; Solvent Method
JOURNAL NAME:
Journal of Crystallization Process and Technology,
Vol.4 No.1,
January
8,
2014
ABSTRACT: Objective: To determine the transformation between two known crystal
forms of the title compound (C18H23NO3, Mr = 301.37). Methods: To recrystallize or heat the crystals and determine
the crystal form by testing the melting points. Results: Both the two known
crystal forms of the title compound can be changed by dissolving into different
organic solvents such as acetone and ethyl acetate. Crystal form I was not influenced by heating while crystal form II can be transformed to crystal form I through melting method. Conclusion: Organic solvents have significant
influences on the two crystal forms of title compound. Crystal form I shows a better thermal stability than crystal form II.